newsfilter
← Latest News
GlobeNewswire·

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc.